In September 2017, a ground-breaking pre-clinical study was published in Nature Communication (Verhoef et al., 2017) presenting VMX-COO1 as a potential safe and effective reversal agent for prevention and treatment of bleeding in the presence of factor Xa inhibitors. These inhibitors are often used as blood thinners by patients who are at risk of venous thrombosis or stroke, but can cause bleeding as a side-effect. The factor Xa from the venom of one of the most venomous snake in the world - the Australian brown snake named Pseudonaja textilis - was the source of inspiration for the creation VMX-COO1. Venom factor Xa causes human blood to clot even in the presence of factor Xa inhibitors. Researchers of the LUMC identified the cause for this and build it into human factor Xa. The result was the engineered 'human' protein VMX-COO1 that also clots blood in the presence of factor Xa inhibitors. VMX-COO1 therefore has the promise to immediately restore hemostasis in patients taking factor Xa inhibitors using natural pathways of blood coagulation. VarmX aims to bring this potential best-in-class reversal agent to the clinic.
VMX-C001 is intended to restore hemostasis in patients with high concentrations of factor Xa inhibitors in their blood.